Ascent

State-of-the-art
molecular AI

Success-contingent pricing

Ascent is a boutique life sciences AI consulting firm specialized in deploying frontier artificial intelligence models for your small molecule drug discovery programs. The majority of our fees are contingent on wet-lab success.

Explore our approach

01 / The Thesis

The economics of molecular AI should reflect experimental reality

AI-generated candidates are hypotheses until biology confirms them; Our commercial structure is built around that fact.

02 / Tenets

Three commitments, applied to every program

They govern how the work is priced, how the biology is approached, and which models are allowed near your program.

I

Success-Contingent Pricing

Our economics move only when your program does.

Our economics are intentionally structured around successful wet-lab validation. Engagements are designed as parallel shots on goal with limited upfront exposure, so the economics move only when the program does. Artificial intelligence tools are predictive, not deterministic. No company or model can guarantee success. Our primary fees are therefore earned only when our predictions translate experimentally, ensuring aligned incentives.
We win when our clients win.

II

Designed Biological Interrogation

Design against the biological question, not a chemical haystack.

Frontier artificial intelligence models have begun to fundamentally transform drug discovery from stochastic search to intentional design. Traditional high-throughput screening relies on chance, sifting through massive physical libraries to find a single needle in a haystack. Ascent reverses this paradigm:
we use frontier generative models to design the exact ‘needles’ required, engineering tailored small molecules directly for your specified targets and pockets. The result is a more directed search across biology: multiple binding sites can be explored in parallel, domain-specific function interrogated, and previously inaccessible targets pursued without the brute-force burden.
We replace stochastic search with directed biological design.

III

Program-Specific Artificial Intelligence

First the biology, then the tools. Never the reverse.

Our artificial intelligence strategies are precisely designed around your biology. We are tool-agnostic and success-focused, carefully orchestrating and deploying leading artificial intelligence models to maximize both your and our odds of success. Current AI platforms ask you to put all your eggs into their singular AI basket. Ascent starts from the biological problem: first define it, then select the tools, then earn the majority of the fee through experimental performance. We treat every asset as we would our own.

03 / Commercial Structure

A deliberately different allocation of risk

Frontier artificial intelligence is often sold as platform access. Ascent offers a different model: focused program execution, with primary fees earned after wet-lab validation.

The platform model

Pay for access

  • Large upfront commitment
  • One vendor’s model worldview
  • Client absorbs execution risk
  • Fees paid regardless of outcome

The Ascent model

Pay for outcomes

  • Focused engagement around one program
  • Models selected for problem fit
  • Ascent owns execution risk
  • Majority fees earned after validation

Ownership and confidentiality

The work remains yours

Clients retain 100% of program IP and generated outputs. Ascent takes no royalties, biobucks, equity ownership, or downstream economic rights.

Client sequences, structures, proprietary data, generated designs, and deliverables are never reused, redelivered, incorporated into another engagement, or added to model-training and reusable datasets.

04 / Capabilities

Molecular design for your biology

Frontier models have unlocked deep, novel exploration of chemical spaces designed directly for your biology. We bring these frontiers to you.

I

Small Molecule Drug Discovery

Our focus is single-shot hit discovery.

Ascent deploys frontier artificial intelligence to design small molecules directly against your targets. Our aim is simple – a single-shot, meticulously designed set of compounds optimized for activity, novelty, diversity, and developability. The goal: to provide you with deep leverage for your molecular discovery programs with a diverse set of high quality starting chemistry across multiple plausible druggable pockets. Instead of a million-compound screen, we aim for two hundred compounds, or less, with majority fees tied to successful in vitro validation. The result: a de-risked, asymmetric shot-on-goal that preserves runway and maximizes upside.

We work closely with your teams to understand your targets and biology deeply, while deploying advanced AI/ML to define druggable, cryptic, and allosteric pockets. Our direct-to-pocket generation technologies allow us to diversify chemical matter against established binding sites, pursue previously ‘undruggable’ targets, and explore domain and pocket-specific druggability. Fundamentally, we aim for unprecedented biological interrogation at a deeply comprehensive scale. 

II

Target Design

We employ deep target intelligence.

We combine deep target research with AI-driven pocket searchers to design precise molecules for your targets. In addition, we sell our research and software directly.

We build maps of your target's plausible druggable sites, and build software on top of established 3D molecular visualization tools for a distinct, intuitive, and lucid viewing experience of your target and its pockets.

05 / Contact

Tell us about your program

Thank you for your interest in Ascent. Please tell us about your program needs and we will get back to you. We accept clients on a rolling basis.

Program inquiry

Start a conversation

Direct submission